Inclusion of Vpr accessory gene in a plasmid vaccine cocktail markedly reduces Nef vaccine effectiveness in vivo resulting in CD4 cell loss and increased viral loads in rhesus macaques.
We compared the immunogenicity of plasmid vaccines containing multiple human immunodeficiency virus (HIV) antigens and found that covaccination with plasmids expressing HIV-1 14 kDa vpr gene product profoundly reduces antigen-specific CD8-mediated cytotoxic T-cell activity (CTL). Interestingly, Th1 type responses against codelivered antigens (pGag-Pol, pNef, etc.) encoded by the plasmid vaccines were suppressed. This suggested that vpr might compromise CD8 T-cell immunity in vivo during infection. A pilot primate vaccine study was designed to test the hypothesis to compare the following groups: unvaccinated controls, animals vaccinated without simean immunodeficiency virus (SIV)-Nef antigen plasmid, and animals covaccinated with the identical plasmid antigen and a plasmid construct encoding SIV Vpr/Vpx. Animals were subsequently challenged intrarectally with pathogenic SIVmac251 after the final vaccination of a multiple immunization protocol. Control animals were all infected and exhibited high viral loads and rapid CD4+ T-cell loss. In contrast, the Nef plasmid-vaccinated animals were also infected but exhibited preservation of CD4+ T-cells and a multilog reduction in viral load compared with controls. Animals covaccinated multiple times with the Nef vaccine and pVpr/Vpx plasmid suffered rapid and profound loss of CD4+ T-cells. These results have important implications for the design of multicomponent and particle vaccines for HIV-1 as well as for our understanding of HIV/SIV pathogenesis in vivo.
Muthumani
K
K
Department of Pathology & Laboratory Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
Bagarazzi
M
M
Conway
D
D
Hwang
D S
DS
Ayyavoo
V
V
Zhang
D
D
Manson
K
K
Kim
J
J
Boyer
J
J
Weiner
D B
DB
D000818:Animals; D018791:CD4 Lymphocyte Count; D015496:CD4-Positive T-Lymphocytes / Q000166:cytology* / Q000276:immunology; D004195:Disease Models, Animal; D005260:Female; D015693:Gene Products, nef / Q000235:genetics / Q000276:immunology*; D016336:Gene Products, vpr / Q000235:genetics / Q000276:immunology*; D016015:Logistic Models; D008213:Lymphocyte Activation; D008253:Macaca mulatta / Q000276:immunology* / Q000821:virology*; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D010957:Plasmids / Q000235:genetics; D012367:RNA, Viral / Q000097:blood / Q000235:genetics; D018449:SAIDS Vaccines / Q000235:genetics* / Q000276:immunology*; D016097:Simian Acquired Immunodeficiency Syndrome / Q000276:immunology / Q000517:prevention & control; D015302:Simian Immunodeficiency Virus / Q000235:genetics / Q000276:immunology* / Q000502:physiology; D013997:Time Factors; D019444:Vaccines, DNA / Q000235:genetics / Q000276:immunology; D019562:Viral Load
D015693:Gene Products, nef; D016336:Gene Products, vpr; D012367:RNA, Viral; D018449:SAIDS Vaccines; D019444:Vaccines, DNA